AIM ImmunoTech Inc AIM

ASE: AIM | ISIN: US00901B1052   18:53
0,410 USD (-3,71%)
(-3,71%)   18:53
Grafiek AIM ImmunoTech Inc Grafiek AIM ImmunoTech Inc

AIM ImmunoTech Inc in het nieuws

27 maart 2023 · AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast · Persbericht

16 maart 2023 · AIM ImmunoTech Announces Late-Breaking Presentation at the International Conference on Antiviral Research Regarding Ampligen as a Potential Therapy Against Ebola Virus Disease · Persbericht

8 maart 2023 · AIM ImmunoTech Announces Publication of New Analysis of the Mechanism of Action of Ampligen as a Potential Prophylactic Therapy Against Ebola Virus Disease · Persbericht

6 maart 2023 · AIM ImmunoTech Issues Letter to Stockholders · Persbericht

17 januari 2023 · AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center · Persbericht

9 januari 2023 · AIM ImmunoTech Broadens Patent Portfolio with New Netherlands Utility Patent Covering Ampligen® and Other AIM-Developed dsRNA Products to Include Rugged dsRNA for Use in COVID-19 Treatment or Prevention · Persbericht

8 december 2022 · AIM ImmunoTech Reports Positive Safety, Tolerability and Biological Activity Data for Intranasal Ampligen® (Rintatolimod) in Healthy Subjects · Persbericht

14 november 2022 · AIM ImmunoTech Announces Presentation of New Data from Roswell Park Comprehensive Cancer Center Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Breast Cancer · Persbericht

12 oktober 2022 · AIM ImmunoTech Announces FDA Clearance of IND Application to Evaluate Ampligen® in Phase 2 Clinical Study for the Treatment of Post-COVID Conditions · Persbericht

18 augustus 2022 · AIM ImmunoTech Announces Commencement of Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer · Persbericht

336x280

Profiel AIM ImmunoTech Inc

Biotechnologie
Gezondheidstechnologie
Productie
Productie van biologische producten

Website: aimimmuno.com

Hoofdzetel: Ocala, Florida vlag Verenigde Staten

CEO: Thomas Equels

Werknemers: 22

Aandelen AIM ImmunoTech Inc

Beurswaarde: 20,47 miljoen USD

Effecten: 48,05 miljoen

Winst per aandeel (12 maand):  PLUS

Beta: 0,61

Mijn selecties